Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity

BACKGROUND: Eleven tau immunoglobulin G (IgG) antibodies have entered clinical trials to treat tauopathies, including Alzheimer's disease, but it is unclear which IgG subclass/subtype has the ideal efficacy and safety profile. Only two subtypes, with or without effector function, have been exam...

Descripción completa

Detalles Bibliográficos
Autores principales: Congdon, Erin E., Pan, Ruimin, Jiang, Yixiang, Sandusky-Beltran, Leslie A., Dodge, Andie, Lin, Yan, Liu, Mengyu, Kuo, Min-Hao, Kong, Xiang-Peng, Sigurdsson, Einar M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475275/
https://www.ncbi.nlm.nih.gov/pubmed/36099813
http://dx.doi.org/10.1016/j.ebiom.2022.104249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475275/
https://www.ncbi.nlm.nih.gov/pubmed/36099813
http://dx.doi.org/10.1016/j.ebiom.2022.104249

Ejemplares similares